Edgewise Therapeutics, Inc. Investing Cash Flow
Edgewise Therapeutics, Inc. (EWTX) reported Investing Cash Flow of $80.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $78.49M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $2.43M, a 94.46% decline year-over-year.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $49.76M, a 137.85% increase year-over-year.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $35.72M, a 40.82% increase year-over-year.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$32.79M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$184.66M, a 279.48% decline from fiscal 2023.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $102.89M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$70.58M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $78.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $80.92M 10-Q · filed 2026-08-06 | $130.69M derived: sum of 3 quarters · filed 2026-08-06 | $166.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.43M 10-Q · filed 2026-05-07 | $52.20M derived: sum of 2 quarters · filed 2026-05-07 | $87.91M derived: sum of 3 quarters · filed 2026-05-07 | -$74.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $49.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.48M derived: sum of 2 quarters · filed 2026-02-26 | -$76.69M derived: sum of 3 quarters · filed 2026-08-06 | -$32.79M 10-K · filed 2026-02-26 |
| 2025-09-30 | $35.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$126.45M derived: sum of 2 quarters · filed 2026-08-06 | -$82.55M 10-Q · filed 2025-11-06 | -$61.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$162.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$118.27M 10-Q · filed 2026-08-06 | -$97.35M derived: sum of 3 quarters · filed 2026-08-06 | -$71.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.90M 10-Q · filed 2026-05-07 | $64.82M derived: sum of 2 quarters · filed 2026-05-07 | $90.18M derived: sum of 3 quarters · filed 2026-05-07 | $127.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.28M derived: sum of 2 quarters · filed 2026-02-26 | $83.65M derived: sum of 3 quarters · filed 2026-02-26 | -$184.66M 10-K · filed 2026-02-26 |
| 2024-09-30 | $25.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $62.73M derived: sum of 2 quarters · filed 2025-11-06 | -$205.58M 10-Q · filed 2025-11-06 | -$178.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $37.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$230.94M 10-Q · filed 2025-08-07 | -$203.96M derived: sum of 3 quarters · filed 2026-02-26 | -$180.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$268.31M 10-Q · filed 2025-05-08 | -$241.32M derived: sum of 2 quarters · filed 2026-02-26 | -$217.91M derived: sum of 3 quarters · filed 2026-02-26 | -$214.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $26.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.40M derived: sum of 2 quarters · filed 2026-02-26 | $53.84M derived: sum of 3 quarters · filed 2026-02-26 | $102.89M 10-K · filed 2026-02-26 |
| 2023-09-30 | $23.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $26.86M derived: sum of 2 quarters · filed 2024-11-07 | $75.90M 10-Q · filed 2024-11-07 | $307.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $52.48M 10-Q · filed 2024-08-08 | -$23.11M derived: sum of 3 quarters · filed 2024-08-08 | -$49.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $49.04M 10-Q · filed 2024-05-09 | -$26.55M derived: sum of 2 quarters · filed 2024-05-09 | -$52.88M derived: sum of 3 quarters · filed 2024-05-09 | -$52.92M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$75.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$101.92M derived: sum of 2 quarters · filed 2024-02-22 | -$101.96M derived: sum of 3 quarters · filed 2024-02-22 | -$70.58M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$26.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$26.37M derived: sum of 2 quarters · filed 2023-11-09 | $5.02M 10-Q · filed 2023-11-09 | $19.14M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $31.34M 10-Q · filed 2023-08-10 | $45.46M derived: sum of 3 quarters · filed 2023-08-10 | $13.85M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $31.39M 10-Q · filed 2023-05-11 | $45.51M derived: sum of 2 quarters · filed 2023-05-11 | $13.90M derived: sum of 3 quarters · filed 2023-05-11 | -$146.07M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $14.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$17.49M derived: sum of 2 quarters · filed 2023-02-23 | -$177.45M derived: sum of 3 quarters · filed 2023-02-23 | -$242.23M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$31.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$191.57M derived: sum of 2 quarters · filed 2022-11-03 | -$256.35M 10-Q · filed 2022-11-03 | -$280.53M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$159.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$224.74M 10-Q · filed 2022-08-04 | -$248.92M derived: sum of 3 quarters · filed 2022-08-04 | -$248.92M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$64.77M 10-Q · filed 2022-05-11 | -$88.95M derived: sum of 2 quarters · filed 2022-05-11 | -$88.96M derived: sum of 3 quarters · filed 2022-05-11 | -$89.14M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$24.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$24.18M derived: sum of 2 quarters · filed 2022-02-24 | -$24.37M derived: sum of 3 quarters · filed 2022-02-24 | -$24.38M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$194.00K derived: sum of 2 quarters · filed 2021-11-10 | -$203.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$197.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$9.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |